Melanotan II tanning injections and nasal sprays
Last updated: October 27, 2026 · 6 min read · By the Grey Peptides Editorial Board
- Melanotan II is a synthetic analog of the hormone that darkens skin, sold online as tanning injections and nasal sprays. It is not approved in the UK, Australia or the US, and regulators in all three have warned against it.
- Dermatology journals have published case reports of melanoma in young users, including one in the mouth of a 22-year-old who used a nasal spray, and of moles appearing or changing. Case reports cannot prove the drug caused them, and a 2019 review found the published data did not allow the risk to be assessed.
- Afamelanotide, the related drug approved as Scenesse, is no endorsement: it is a clinician-inserted implant for a rare light-sensitivity disease, and its own label calls for full-body skin checks twice a year.
What melanotan II is
Melanotan II Medium is a synthetic, ring-shaped analog of part of alpha-melanocyte-stimulating hormone, the body's signal to make pigment 1. Through the melanocortin 1 receptor it darkens the skin 2. It was given to people in a 1996 pilot in three men: injections on alternate days, with saline on the days between, over two weeks. One of two men on the highest dose had sleepiness and fatigue, mild nausea was reported at most doses, spontaneous erections followed dosing, and two of the three men darkened 1. It has never become an approved medicine; Australia's regulator says its development was halted for safety reasons 3. Our melanotan II entry grades its evidence as medium.
How it is sold and used
Melanotan II is sold online as injections and as nasal sprays 4 5. A study of UK and Irish online forums from January 2016 to October 2017 collected 623 posts from 205 people discussing their use; motivations included a tan before sun holidays and fitness or bodybuilding competitions 2. Its authors warned clinicians about the risks to pigmented skin lesions and about hazards beyond the skin: transmission of infectious diseases, potentially contaminated products, polypharmacy and sunbed exposure 2. Because the product is unlicensed, no regulator has checked what a vial or spray contains.
Moles and melanoma: what the case reports show
The concern that brings dermatologists into this is melanoma. In a 2014 report, a 20-year-old woman with fair skin who used melanotan II together with tanning beds was found to have a melanoma, confirmed on histology, with intensely pigmented skin all over 6. A 2012 report described melanoma in situ in a melanotan user and noted earlier reports of atypical moles and melanoma with these peptides 7. A 2025 report described a 22-year-old woman who used a melanotan II nasal spray for tanning and developed a malignant melanoma in the lining of her upper jaw, treated with surgery and immunotherapy 5.
Moles can also appear suddenly. A 2019 review of eruptive melanocytic naevi gathered 179 patients from 93 articles; immunosuppressive drugs, chemotherapy or melanotan were the suspected cause in 41%, and 16% had at least one atypical (dysplastic) mole confirmed under the microscope 8.
What these reports cannot do is prove cause. Each describes individuals, sometimes with other risks, such as the tanning beds in the 2014 case 6. The 2019 review reported five cases of associated melanoma and said the nature of the data precluded assessing the risk of malignant change 8; the 2014 authors wrote that, because the drug is unlicensed and incompletely tested, the extent and types of its adverse effects are unknown, and advised clinicians to counsel at-risk patients 6. The reports are warnings, not a measurement of how often harm follows.
Other reported harms
Melanotan II's effects go beyond the skin: the 1996 pilot recorded spontaneous erections after dosing 1, and the drug has been investigated for erectile dysfunction 9. A 2021 report described a man with acute ischaemic priapism after injecting it who needed surgical decompression, the third such case published 9. By 2013 the UK regulator, the MHRA, had received 18 reports describing 74 reactions to melanotan products, including stomach and heart problems and blood and eye disorders 4.
What regulators say
In the UK, the MHRA warned the public in August 2013 against unlicensed tanning injections and nasal sprays containing melanotan, and had closed 72 websites offering it to UK customers in the previous three months 4. In Australia, melanotan II has not been cleared by the Therapeutic Goods Administration; a TGA spokesperson said its development as a potential medicine "was halted some years ago due to safety reasons", and promoting or selling it to the public is against the law 3. In the US, FDA sent a warning letter in 2007 to a Tennessee company selling melanotan II as a tanning agent with claims of protection against skin cancer and rosacea, called it an unapproved product, and advised consumers to stop using it 10; news reports at the time described the letter as finding it unapproved and mislabelled 11.
What afamelanotide's approval does and doesn't mean
Afamelanotide High is a related but different analog of the same hormone, and its approval says nothing about melanotan II's safety. Afamelanotide was approved in the US on October 8, 2019 12, as Scenesse, to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare disease that makes light painful 13. It is an implant inserted under the skin every two months by a health care professional who has completed the maker's training in the procedure 13.
Its label is the best answer to the safety argument. It warns that the drug can darken existing moles and freckles, recommends a full-body skin examination twice a year to watch existing and new pigmented lesions, and warns of serious hypersensitivity reactions, including anaphylaxis, reported after marketing 13. The approved drug comes with those skin checks in its label; an unlicensed spray comes with no label at all. Our afamelanotide entry covers it in full, and bremelanotide High is another melanocortin drug, approved for a different purpose.
Frequently asked questions
Is melanotan II legal?
It is not approved in the UK, Australia or the US. The MHRA warned against it in 2013, promoting or selling it to the public in Australia is against the law, and FDA warned a US seller in 2007 that it was an unapproved product.
Does melanotan cause melanoma?
That is not proven. Dermatology journals have published case reports of melanoma and of moles appearing or changing in users, but case reports cannot establish cause, and a 2019 review said the data did not allow the risk to be assessed.
Is the nasal spray safer than the injection?
We found no evidence that it is. A 2025 case report describes an oral melanoma in a 22-year-old who used a melanotan II nasal spray, and the MHRA's 2013 warning covered nasal sprays and injections alike.
What is Scenesse?
Scenesse is afamelanotide, a related but different drug approved in the US in 2019 as an implant for erythropoietic protoporphyria. Its label recommends full-body skin examinations twice a year.
Does melanotan II tan the skin?
Yes, it darkens skin through the melanocortin 1 receptor, which is why it is sold. FDA's 2007 warning concerned a product marketed with claims of protection against skin cancer, which FDA called unapproved, and case reports describe melanoma in users.
Related on Grey Peptides
- What research use only really means
- Peptide clinics: 12 questions to ask before you pay
- Podcast peptide claims, fact-checked
Sources
- Dorr, R. T., Lines, R., Levine, N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci, 58(20), 1777-84. PMID: 8637402
- Gilhooley, E., Daly, S., McKenna, D. (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology, 237(6), 995-999. PMID: 34464955
- UNSW Sydney Newsroom (M. Massy-Westropp). What is Melanotan-II, the drug that the TGA urges consumers to avoid? January 30, 2023, quoting a Therapeutic Goods Administration spokesperson; re-read October 27, 2026.
- Medicines and Healthcare products Regulatory Agency (UK). Warning on unlicensed tanning injections and nasal sprays containing melanotan, as reported by Get Safe Online, "Warning about tanning injections", August 31, 2013 (18 reports, 74 reactions, 72 websites closed in three months); re-read October 27, 2026.
- Yassin, A., Bhujel, N., Singh, R. P. (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. Int J Oral Maxillofac Surg, 54(9), 806-808. PMID: 40210573
- Hjuler, K. F., Lorentzen, H. F. (2014). Melanoma associated with the use of melanotan-II. Dermatology, 228(1), 34-6. PMID: 24355990
- Ong, S., Bowling, J. (2012). Melanotan-associated melanoma in situ. Australas J Dermatol, 53(4), 301-2. PMID: 22724573
- Burian, E. A., Jemec, G. B. E. (2019). Eruptive Melanocytic Nevi: A Review. Am J Clin Dermatol, 20(5), 669-682. PMID: 31119650
- Mallory, C. W., Lopategui, D. M., Cordon, B. H. (2021). Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med, 9(1), 100298. PMID: 33460908
- US Food and Drug Administration. Consumer update on Melanotan II, posted September 5, 2007 ("an unapproved product"; marketed as "effective in protecting against skin cancer and rosacea"; FDA "advising consumers to stop using Melanotan II"), as preserved in the University of North Texas federal web archive (End of Term 2008 crawl, fda.gov/consumer/updates/melanotan090507.html); read October 27, 2026.
- HealthDay. FDA Halts Sale of Injectable Tanning Product (September 6, 2007): a Tennessee-based company, "unapproved and mislabeled"; U.S. Pharmacist, FDA Fast Facts (October 18, 2007); re-read October 27, 2026.
- US Food and Drug Administration. Drugs@FDA (openFDA): SCENESSE (afamelanotide), NDA 210797, original approval October 8, 2019; read October 2, 2026.
- Scenesse (afamelanotide) implant US prescribing information, DailyMed set 94f53286-11dd-7fbb-e053-2a95a90a7c48, version 11, effective May 11, 2026 (confirmed current on DailyMed October 27, 2026). DailyMed
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead